Voyager Therapeutics, Inc. VYGR
1.83 USD +0.05 (+2.81%)
At closeNov 3, 2026, 4:04 PM EST
1.83 0.00 0.00%
After hours · Nov 3, 4:04 PM ET
1.79 Day range 1.87
1.68 52-week range 5.48
- YTD
- -53.44%
- 1 year
- -60.13%
Analyst view
Price target (mean) 17.10 +834.4% upside
Now 1.83
- Target (low)
- 11.00
- Target (mean)
- 17.10
- Target (high)
- 30.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 9
- 2 months ago 10
- 3 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.34035 | -0.48 – -0.08 | 1.25 | -127.2% | 17.18M | -80.9% | 9 |
| Next quarter | -0.46593 | -0.72 – -0.27 | -0.20 | -133.0% | 11.68M | -40.1% | 6 |
| Current year | -0.90569 | -1.17 – -0.44 | 2.97 | -130.5% | 90.89M | -63.6% | 9 |
| Next year | -1.41 | -2.96 – -0.41 | -0.90569 | -55.8% | 72.62M | -20.1% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Citigroup | Initiated | — | Buy |
| Nov 14, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 16, 2024 | Leerink Partners | Initiated | — | Outperform |
| Aug 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2024 | Wedbush | Maintained | Neutral | Neutral |
| Jul 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 14, 2024 | Wedbush | Maintained | Neutral | Neutral |
| Mar 26, 2024 | Guggenheim | Initiated | — | Buy |
| Mar 19, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 7, 2024 | Citigroup | Initiated | — | Buy |
| Jan 2, 2024 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Aug 7, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 10, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| May 10, 2023 | Truist Securities | Initiated | — | Buy |
| Mar 10, 2023 | Oppenheimer | Initiated | — | Outperform |
| Nov 3, 2021 | Chardan Capital | Maintained | — | Neutral |
| Oct 7, 2021 | Baird | Upgrade | Neutral | Outperform |
| Apr 19, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 26, 2021 | Baird | Downgrade | Outperform | Neutral |
| Feb 3, 2021 | Wedbush | Downgrade | Outperform | Neutral |
| Feb 3, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 3, 2021 | BTIG | Downgrade | Buy | Neutral |
| Nov 11, 2020 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 10, 2020 | Raymond James | Downgrade | Strong Buy | Outperform |
| Nov 10, 2020 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Aug 4, 2020 | HC Wainwright & Co. | Maintained | — | Buy |